193 related articles for article (PubMed ID: 36045346)
41. NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma.
Leventaki V; Drakos E; Medeiros LJ; Lim MS; Elenitoba-Johnson KS; Claret FX; Rassidakis GZ
Blood; 2007 Sep; 110(5):1621-30. PubMed ID: 17416736
[TBL] [Abstract][Full Text] [Related]
42. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma.
Amin HM; McDonnell TJ; Ma Y; Lin Q; Fujio Y; Kunisada K; Leventaki V; Das P; Rassidakis GZ; Cutler C; Medeiros LJ; Lai R
Oncogene; 2004 Jul; 23(32):5426-34. PubMed ID: 15184887
[TBL] [Abstract][Full Text] [Related]
43. Brefeldin A exerts differential effects on anaplastic lymphoma kinase positive anaplastic large cell lymphoma and classical Hodgkin lymphoma cell lines.
Toda T; Watanabe M; Kawato J; Kadin ME; Higashihara M; Kunisada T; Umezawa K; Horie R
Br J Haematol; 2015 Sep; 170(6):837-46. PubMed ID: 26105086
[TBL] [Abstract][Full Text] [Related]
44. Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.
Ceccon M; Merlo MEB; Mologni L; Poggio T; Varesio LM; Menotti M; Bombelli S; Rigolio R; Manazza AD; Di Giacomo F; Ambrogio C; Giudici G; Casati C; Mastini C; Compagno M; Turner SD; Gambacorti-Passerini C; Chiarle R; Voena C
Oncogene; 2016 Jul; 35(29):3854-3865. PubMed ID: 26657151
[TBL] [Abstract][Full Text] [Related]
45. STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression.
Zhang Q; Wang HY; Liu X; Wasik MA
Nat Med; 2007 Nov; 13(11):1341-8. PubMed ID: 17922009
[TBL] [Abstract][Full Text] [Related]
46. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.
Han Y; Amin HM; Franko B; Frantz C; Shi X; Lai R
Blood; 2006 Oct; 108(8):2796-803. PubMed ID: 16825495
[TBL] [Abstract][Full Text] [Related]
47. Regulation of CD45 phosphatase by oncogenic ALK in anaplastic large cell lymphoma.
Mura G; Karaca Atabay E; Menotti M; Martinengo C; Ambrogio C; Giacomello G; Arigoni M; Olivero M; Calogero RA; Chiarle R; Voena C
Front Oncol; 2022; 12():1085672. PubMed ID: 36698412
[TBL] [Abstract][Full Text] [Related]
48. ALK-transformed mature T lymphocytes restore early thymus progenitor features.
Congras A; Hoareau-Aveilla C; Caillet N; Tosolini M; Villarese P; Cieslak A; Rodriguez L; Asnafi V; Macintyre E; Egger G; Brousset P; Lamant L; Meggetto F
J Clin Invest; 2020 Dec; 130(12):6395-6408. PubMed ID: 33141118
[TBL] [Abstract][Full Text] [Related]
49. NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells.
Ambrogio C; Martinengo C; Voena C; Tondat F; Riera L; di Celle PF; Inghirami G; Chiarle R
Cancer Res; 2009 Nov; 69(22):8611-9. PubMed ID: 19887607
[TBL] [Abstract][Full Text] [Related]
50. EBP2, a novel NPM-ALK-interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53.
Uchihara Y; Tago K; Tamura H; Funakoshi-Tago M
Mol Oncol; 2021 Jan; 15(1):167-194. PubMed ID: 33040459
[TBL] [Abstract][Full Text] [Related]
51. The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma.
Atsaves V; Lekakis L; Drakos E; Leventaki V; Ghaderi M; Baltatzis GE; Chioureas D; Jones D; Feretzaki M; Liakou C; Panayiotidis P; Gorgoulis V; Patsouris E; Medeiros LJ; Claret FX; Rassidakis GZ
Br J Haematol; 2014 Nov; 167(4):514-23. PubMed ID: 25145835
[TBL] [Abstract][Full Text] [Related]
52. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.
Galkin AV; Melnick JS; Kim S; Hood TL; Li N; Li L; Xia G; Steensma R; Chopiuk G; Jiang J; Wan Y; Ding P; Liu Y; Sun F; Schultz PG; Gray NS; Warmuth M
Proc Natl Acad Sci U S A; 2007 Jan; 104(1):270-5. PubMed ID: 17185414
[TBL] [Abstract][Full Text] [Related]
53. miR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells.
Hoareau-Aveilla C; Quelen C; Congras A; Caillet N; Labourdette D; Dozier C; Brousset P; Lamant L; Meggetto F
Haematologica; 2019 Feb; 104(2):347-359. PubMed ID: 30262555
[TBL] [Abstract][Full Text] [Related]
54. Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches.
Wasik MA; Zhang Q; Marzec M; Kasprzycka M; Wang HY; Liu X
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S27-35. PubMed ID: 19393833
[TBL] [Abstract][Full Text] [Related]
55. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.
Zhang Q; Raghunath PN; Xue L; Majewski M; Carpentieri DF; Odum N; Morris S; Skorski T; Wasik MA
J Immunol; 2002 Jan; 168(1):466-74. PubMed ID: 11751994
[TBL] [Abstract][Full Text] [Related]
56. Pathobiology of ALK+ anaplastic large-cell lymphoma.
Amin HM; Lai R
Blood; 2007 Oct; 110(7):2259-67. PubMed ID: 17519389
[TBL] [Abstract][Full Text] [Related]
57. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.
Ambrogio C; Voena C; Manazza AD; Martinengo C; Costa C; Kirchhausen T; Hirsch E; Inghirami G; Chiarle R
Cancer Res; 2008 Nov; 68(21):8899-907. PubMed ID: 18974134
[TBL] [Abstract][Full Text] [Related]
58. Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.
Tsuyama N; Sakamoto K; Sakata S; Dobashi A; Takeuchi K
J Clin Exp Hematop; 2017; 57(3):120-142. PubMed ID: 29279550
[TBL] [Abstract][Full Text] [Related]
59. LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling.
Xiao Q; Dong M; Cheng F; Mao F; Zong W; Wu K; Wang H; Xie R; Wang B; Lei T; Guo D
Int J Oncol; 2018 Sep; 53(3):1069-1082. PubMed ID: 30015847
[TBL] [Abstract][Full Text] [Related]
60. The biology and management of systemic anaplastic large cell lymphoma.
Hapgood G; Savage KJ
Blood; 2015 Jul; 126(1):17-25. PubMed ID: 25869285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]